1 / 11

Topical Bevacizumab eyedrops for corneal neovascularisation preliminary results

Topical Bevacizumab eyedrops for corneal neovascularisation preliminary results. Siveková D., Netuková M., Liehneová K., Vokrojová M., Kuchynka P., Studený P. Department of Ophthalmology , 3rd Medical Faculty , Charles University, Prague , Czech Republic.

star
Download Presentation

Topical Bevacizumab eyedrops for corneal neovascularisation preliminary results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Topical Bevacizumabeyedropsfor corneal neovascularisationpreliminary results Siveková D., Netuková M., Liehneová K., Vokrojová M., Kuchynka P., Studený P. Department ofOphthalmology, 3rd MedicalFaculty, Charles University, Prague, CzechRepublic The authors have no financial interest in the presentation material

  2. Purpose To present preliminary results of using topical Bevacizumab in patients with corneal neovascularisation.

  3. Materialsandmethods • Prospective study – under termis and conditions of ethical committee of 3rd Medical faculty, Charles University, Prague. All patients were fully informed and signed a consent form • 14 eyes of 13 consecutive adult patients (4 men, 9 women) • Mean age 59 years (42 – 81) • Follow up time 3 months

  4. Indications in our study • Pterygium 3x • Leucomacorneae 4x • Riskkeratoplasty 4x • Neovascularisationafterkeratitis 1x • St.p. acid burn 1x

  5. Aplicationandclinicalevaluation Aplication • Bevacizumab eye drops (2,5mg/ml) – OFF LABEL USE • 2 times daily for 14 days • Completeophthalmicexaminationincluding BCVA, IOP, biomicroscopy, fundus – beforeandafter 1, 2 and 3 month • Digital photographsofthecornea • Cornealpatternforgrading 96 identicaltriangels (72 peripheral, 24 central) • Evaluationwasmade by 1 doctor Clinicalevaluation

  6. Results Centralsegments Peripheralsegments Statistically significant change 1 and 3 months after treatment in peripheral segments (p=0,003) No statistically significant change 1 and 3 months after treatment in central segments (p>0,05)

  7. Results BCVA

  8. Month 3 Before Month 1

  9. Month 3 Before Month 1

  10. Month 3 Before Month 1

  11. Conclusion • The short term use of Bevacizumab eye drops seems to be very effective treatment of corneal neovascularisation • We did not note any serious complication during the therapy. In two patients we observed temporarily some small epithelial defects. • Further prospective controlled studies with larger number of patients and long term results are required.

More Related